WallStreetZenWallStreetZen

Sectors & IndustriesHealthcareDrug Manufacturers - General
Best General Drug Manufacturer Stocks to Buy Now (2025)
Top general drug manufacturer stocks in 2025 ranked by overall Zen Rating. "A" Rated stocks have returned an average of +32.52% per year, and are the best general drug manufacturer stocks to buy now. Learn More.

Industry: Drug Manufacturers - Gene...
OverviewZen RatingPriceValue
GrowthFinancialsMomentumSentimentForecastDividendsDue Diligence
A
General Drug Manufacturers is Zen Rated A and is the 4th ranked industry out of 145 stock market industries
Learn how the Zen Ratings work
Ticker
Company
Zen Rating
Price
Value
Graham Fair Value
Graham Fair Value %
P/E
Forward P/E
P/S
P/B
PEG
Free Cash Flow
Free Cash Flow Yield
Book Value
BVPS
EV
EV/EBITDA
BMY
BRISTOL MYERS SQUIBB CO
$52.41$45.5715.00%17.65x7.93x2.22x5.75x0.68x$15.30B14.34%$18.55B9.11$139.95B10.81
GSK
GSK PLC
$48.81N/AN/A13.53x28.56x2.30x4.57xN/A$8.73B8.86%$21.53B10.68$117.72B11.45
LLY
ELI LILLY & CO
$1,027.51$309.14232.37%50.15x42.74x15.51x40.83x1.99x$9.27B1.01%$23.79B26.53$1.00T41.15
GRFS
GRIFOLS SA
$9.14$7.9515.01%35.70x11.80x0.78x0.96x0.52x$357.52M5.69%$6.54B9.51$16.49B9.63
MRK
MERCK & CO INC
$100.30$75.2633.27%13.25x11.07x3.90x4.80x1.18x$13.05B5.21%$51.85B20.78$272.15B9.84
AMGN
AMGEN INC
$317.74$176.4980.04%24.39x14.65x4.75x17.79x1.16x$11.54B6.75%$9.62B17.88$216.24B13.09
GILD
GILEAD SCIENCES INC
$120.40$69.5573.11%18.49x14.46x5.15x6.93x1.40x$9.16B6.12%$21.54B17.33$166.99B12.21
ABBV
ABBVIE INC
$223.32$72.33208.74%167.91x20.57x6.62x-149.39x1.28x$19.68B4.98%-$2.64B-1.49$457.81B36.66
SNY
SANOFI
$48.68$70.48-30.93%11.21x6.15x2.35x1.49x0.40x$11.50B9.64%$82.36B33.60$131.13B7.26
JNJ
JOHNSON & JOHNSON
$211.58$83.84152.36%20.29x19.28x5.53x6.43x3.33x$19.60B3.85%$79.28B32.93$537.32B13.51
AMRN
AMARIN CORP PLC
$14.36N/AN/A-3.42x-14.98x1.32x0.65xN/A-$21.86M-7.33%$458.89M22.09$182.21M-2.27
AZN
ASTRAZENECA PLC
$89.83$81.999.57%29.60x9.59x4.79x6.07x0.51x$12.67B4.55%$45.89B14.79$302.96B15.42
NVS
NOVARTIS AG
$132.57$71.5285.35%17.99x14.55x4.53x5.76x1.70x$19.64B7.69%$44.33B23.02$277.80B9.86
OGN
ORGANON & CO
$7.17$31.40-77.17%3.72x1.88x0.30x2.06x0.13x$780.00M41.84%$906.00M3.49$10.02B6.43
BIIB
BIOGEN INC
$174.10$117.6947.93%15.84x11.46x2.54x1.40x1.19x$2.26B8.86%$18.21B124.20$28.27B10.43
PFE
PFIZER INC
$25.85$23.0712.06%15.03x8.15x2.34x1.58x0.73x$10.38B7.06%$92.80B16.32$207.34B13.09
SCLX
SCILEX HOLDING CO
$16.63N/AN/A-0.52x-0.50x4.78x-0.70xN/A$23.82M12.35%-$179.72M-15.49$192.93M-0.60
MIRA
MIRA PHARMACEUTICALS INC
$1.49N/AN/A-0.57x-1.25xN/A8.26xN/A-$5.33M-18.59%$7.55M0.39$59.75M-10.68
MDCX
MEDICUS PHARMA LTD
$1.89N/AN/A-0.88x-1.93xN/A-45.75xN/A-$19.43M-55.19%-$910.13k-0.05$40.02M-1.35
NSRX
NASUS PHARMA LTD
$6.80N/AN/A-30.91x-7.02xN/AN/AN/A-$665.00k-1.40%-$3.21M-0.46N/AN/A
1

General Drug Manufacturer Stocks FAQ

What are the best general drug manufacturer stocks to buy right now in Dec 2025?

According to Zen Ratings, our proprietary rating system that evaluates 115 factors proven to drive growth in stocks and assigns each stock in our system an overall letter grade as well as 7 individual Component Grades for Value, Growth, Momentum, Sentiment, Safety, Financials, and proprietary AI algorithms, the 3 best general drug manufacturer stocks to buy right now are:

1. Bristol Myers Squibb Co (NYSE:BMY)


Bristol Myers Squibb Co (NYSE:BMY) is the #1 top general drug manufacturer stock out of 20 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Bristol Myers Squibb Co (NYSE:BMY) is: Value: A, Growth: B, Momentum: C, Sentiment: B, Safety: A, Financials: B, and AI: B.

Bristol Myers Squibb Co (NYSE:BMY) has a Due Diligence Score of 52, which is 12 points higher than the general drug manufacturer industry average of 40.

BMY passed 18 out of 38 due diligence checks and has strong fundamentals. Bristol Myers Squibb Co has seen its stock lose -6.88% over the past year, underperforming other general drug manufacturer stocks by -31 percentage points.

Bristol Myers Squibb Co has an average 1 year price target of $51.50, a downside of -1.74% from Bristol Myers Squibb Co's current stock price of $52.41.

Bristol Myers Squibb Co stock has a consensus Hold recommendation according to Wall Street analysts. Of the 6 analysts covering Bristol Myers Squibb Co, 16.67% have issued a Strong Buy rating, 0% have issued a Buy, 66.67% have issued a hold, while 0% have issued a Sell rating, and 16.67% have issued a Strong Sell.

2. Gsk (NYSE:GSK)


Gsk (NYSE:GSK) is the #2 top general drug manufacturer stock out of 20 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Gsk (NYSE:GSK) is: Value: B, Growth: B, Momentum: B, Sentiment: B, Safety: B, Financials: B, and AI: C.

Gsk (NYSE:GSK) has a Due Diligence Score of 36, which is -4 points lower than the general drug manufacturer industry average of 40. Although this number is below the industry average, our proven quant model rates GSK as a "A".

GSK passed 13 out of 38 due diligence checks and has average fundamentals. Gsk has seen its stock return 42.84% over the past year, overperforming other general drug manufacturer stocks by 18 percentage points.

3. Eli Lilly & Co (NYSE:LLY)


Eli Lilly & Co (NYSE:LLY) is the #3 top general drug manufacturer stock out of 20 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Eli Lilly & Co (NYSE:LLY) is: Value: B, Growth: B, Momentum: B, Sentiment: A, Safety: C, Financials: B, and AI: A.

Eli Lilly & Co (NYSE:LLY) has a Due Diligence Score of 60, which is 20 points higher than the general drug manufacturer industry average of 40.

LLY passed 24 out of 38 due diligence checks and has strong fundamentals. Eli Lilly & Co has seen its stock return 31.34% over the past year, overperforming other general drug manufacturer stocks by 7 percentage points.

Eli Lilly & Co has an average 1 year price target of $1,087.93, an upside of 5.88% from Eli Lilly & Co's current stock price of $1,027.51.

Eli Lilly & Co stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 15 analysts covering Eli Lilly & Co, 60% have issued a Strong Buy rating, 20% have issued a Buy, 20% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

What are the general drug manufacturer stocks with highest dividends?

Out of 14 general drug manufacturer stocks that have issued dividends in the past year, the 3 general drug manufacturer stocks with the highest dividend yields are:

1. Organon & Co (NYSE:OGN)


Organon & Co (NYSE:OGN) has an annual dividend yield of 4.74%, which is 2 percentage points higher than the general drug manufacturer industry average of 2.73%. Organon & Co's dividend payout is not stable, having dropped more than 10% one times in the last 10 years. Organon & Co's dividend has not shown consistent growth over the last 10 years.

Organon & Co's dividend payout ratio of 31.1% indicates that its high dividend yield is sustainable for the long-term.

2. Sanofi (NASDAQ:SNY)


Sanofi (NASDAQ:SNY) has an annual dividend yield of 4.54%, which is 2 percentage points higher than the general drug manufacturer industry average of 2.73%. Sanofi's dividend payout is not stable, having dropped more than 10% one times in the last 10 years. Sanofi's dividend has shown consistent growth over the last 10 years.

Sanofi's dividend payout ratio of 51% indicates that its high dividend yield is sustainable for the long-term.

3. Gsk (NYSE:GSK)


Gsk (NYSE:GSK) has an annual dividend yield of 3.43%, which is 1 percentage points higher than the general drug manufacturer industry average of 2.73%. Gsk's dividend payout is not stable, having dropped more than 10% nine times in the last 10 years. Gsk's dividend has not shown consistent growth over the last 10 years.

Gsk's dividend payout ratio of 45.6% indicates that its dividend yield is sustainable for the long-term.

Why are general drug manufacturer stocks up?

General drug manufacturer stocks were up 0.77% in the last day, and down -0.01% over the last week.

We couldn't find a catalyst for why general drug manufacturer stocks are up.

What are the most undervalued general drug manufacturer stocks?

Based on the Valuation rating, one of the 7 components of a stocks overall Zen Ratings grade, which evaluates factors including estimated earnings yield, earnings before interest and taxes/enterprise value, cash flow yield, free cash flow to price, and price-to-earnings growth (PEG ratio), the 3 most undervalued general drug manufacturer stocks right now are:

1. Organon & Co (NYSE:OGN)


Organon & Co (NYSE:OGN) is the most undervalued general drug manufacturer stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Organon & Co has a valuation score of 71, which is 32 points higher than the general drug manufacturer industry average of 39. It passed 5 out of 7 valuation due diligence checks.

Organon & Co's stock has dropped -53.29% in the past year. It has underperformed other stocks in the general drug manufacturer industry by -78 percentage points.

2. Merck & Co (NYSE:MRK)


Merck & Co (NYSE:MRK) is the second most undervalued general drug manufacturer stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Merck & Co has a valuation score of 43, which is 4 points higher than the general drug manufacturer industry average of 39. It passed 3 out of 7 valuation due diligence checks.

Merck & Co's stock has dropped -0.94% in the past year. It has underperformed other stocks in the general drug manufacturer industry by -25 percentage points.

3. Biogen (NASDAQ:BIIB)


Biogen (NASDAQ:BIIB) is the third most undervalued general drug manufacturer stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Biogen has a valuation score of 71, which is 32 points higher than the general drug manufacturer industry average of 39. It passed 5 out of 7 valuation due diligence checks.

Biogen's stock has gained 12.08% in the past year. It has underperformed other stocks in the general drug manufacturer industry by -12 percentage points.

Are general drug manufacturer stocks a good buy now?

37.5% of general drug manufacturer stocks rated by analysts are a strong buy right now. On average, analysts expect general drug manufacturer stocks to rise by 6.18% over the next year.

42.11% of general drug manufacturer stocks have a Zen Rating of A (Strong Buy), 26.32% of general drug manufacturer stocks are rated B (Buy), 21.05% are rated C (Hold), 5.26% are rated D (Sell), and 5.26% are rated F (Strong Sell).

What is the average p/e ratio of the drug manufacturers - general industry?

The average P/E ratio of the drug manufacturers - general industry is 44.67x.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.